Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

The liver is the sixth most common site of primary cancer in humans, and generally arises in
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Liver cancer remains a global health challenge, with an estimated incidence of> 1 million
cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer …

HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …

Background Hepatocellular carcinoma (HCC), the third most prevalent cause of cancer-
related death, is a frequent primary liver cancer with a high rate of morbidity and mortality. T …

Various forms of immunotherapy, such as checkpoint blockade immunotherapy, are proving
to be effective at restoring T cell-mediated immune responses that can lead to marked and …

In contrast to most other malignancies, hepatocellular carcinoma (HCC), which accounts for
approximately 90% of primary liver cancers, arises almost exclusively in the setting of …

Background For patients with advanced hepatocellular carcinoma, sorafenib is the only
approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and …

Hepatocellular carcinoma (HCC) ranks the most common primary liver malignancy and the
third leading cause of tumor-related mortality worldwide. Unfortunately, despite advances in …